SCHEMBL17488264

SCHEMBL17488264

Cc1cnc(Oc2ccc(CNc3nc4ccc(N)cc4n3C)cc2)nc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.48
RAB9A P51151 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 2/20 0.41
KDR P35968 1/20 0.41
TP53 P04637 4/20 0.41
LMNA P02545 3/20 0.41
MAPT P10636 3/20 0.40
THRB P10828 2/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 1/20 0.38
ALOX15 P16050 1/20 0.37
PKM P14618 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17488115 0.94 NPC1 (0.50) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL18960426 0.91 NPC1 (0.48) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL17487767 0.91 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL18960446 0.91 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL17488225 0.89 NPC1 (0.53) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL18960447 0.88 NPC1 (0.47) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL17488114 0.88 NPC1 (0.45) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL17488234 0.88 NPC1 (0.48) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL18960455 0.87 NPC1 (0.44) NPC1RAB9ASMN1; SMN2KMT2AKDR
SCHEMBL17488133 0.86 NPC1 (0.49) NPC1RAB9ASMN1; SMN2KMT2AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 US disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 NPC1 2764/4885RAB9A 3982/4885SMN1; SMN2 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.